These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11017843)

  • 1. Treatment of latent tuberculosis infection in patients aged > or =35 years.
    Gilroy SA; Rogers MA; Blair DC
    Clin Infect Dis; 2000 Sep; 31(3):826-9. PubMed ID: 11017843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
    Jahng AW; Tran T; Bui L; Joyner JL
    Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health and preventive aspects of pulmonary tuberculosis. Infectiousness, epidemiology, risk factors, classification, and preventive therapy.
    Leff A; Geppert EF
    Arch Intern Med; 1979 Dec; 139(12):1405-10. PubMed ID: 518223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Return of tuberculosis: screening and preventive therapy.
    Dowling PT
    Am Fam Physician; 1991 Feb; 43(2):457-67. PubMed ID: 1990732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
    Fernández-Villar A; Sopeña B; Vázquez R; Ulloa F; Fluiters E; Mosteiro M; Martínez-Vázquez C; Piñeiro L
    Clin Infect Dis; 2003 Feb; 36(3):293-8. PubMed ID: 12539070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptance of isoniazid preventive treatment by close contacts of tuberculosis cases: a 692-subject Italian study.
    Codecasa LR; Besozzi G
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):208-12. PubMed ID: 9526192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles.
    Coly A; Morisky D
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):703-10. PubMed ID: 15182139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance to treatment of latent tuberculosis infection in a region of Israel.
    Bibi H; Weiler-Ravell D; Shoseyov D; Feigin I; Arbelli Y; Chemtob D
    Isr Med Assoc J; 2002 Jan; 4(1):13-6. PubMed ID: 11802301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preventive antituberculosis chemotherapy in 250 patients of the antituberculosis outpatient clinic in Lausanne].
    Racine-Perreaud E; Zellweger JP
    Schweiz Med Wochenschr; 1994 Apr; 124(17):705-11. PubMed ID: 8202667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled chemoprophylaxis trials in tuberculosis. A general review.
    Ferebee SH
    Bibl Tuberc; 1970; 26():28-106. PubMed ID: 4903501
    [No Abstract]   [Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003.
    Hoopes AJ; Kammerer JS; Harrington TA; Ijaz K; Armstrong LR
    Arch Intern Med; 2008 Oct; 168(18):1984-92. PubMed ID: 18852399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
    Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS
    Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tuberculosis outbreak in a junior high school in Kochi City--studies on factors relating to extent of tuberculosis infection and the efficacy of isoniazid chemoprophylaxis].
    Toyota M; Morioka S
    Kekkaku; 2001 Sep; 76(9):625-34. PubMed ID: 11676120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid toxicity in health care workers.
    Stuart RL; Wilson J; Grayson ML
    Clin Infect Dis; 1999 Apr; 28(4):895-7. PubMed ID: 10825056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of isoniazid in tuberculosis chemoprophylaxis in children with rising tuberculin sensitivity].
    Mitinskaia LA; Elufimova VF; Iukhimenko NV; Demeshko ND; Zriachkina LI; Pesnia NP
    Probl Tuberk; 1995; (2):5-6. PubMed ID: 7777467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of isoniazid prophylaxis.
    Ferebee SH
    Bull Int Union Tuberc; 1968 Dec; 41():161-6. PubMed ID: 4885376
    [No Abstract]   [Full Text] [Related]  

  • 20. [Principles in the performance of chemotherapy in dispensary group VI children and adolescents].
    Ovsiankina ES; Gubkina MF; Kuz'mina IK; Stakheeva LB; Borodina NN; Zaletina EIu
    Probl Tuberk Bolezn Legk; 2007; (8):25-8. PubMed ID: 17915463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.